Northern Treatment Advisory Group

The purpose of the Northern Treatment Advisory Group (NTAG) is to advise the North East & North Cumbria ICB Medicines Subcommittee on the clinical and cost-effectiveness of new and existing treatments, thereby ensuring equitable access to a clinically defined and appropriate range of treatments for the relevant patient population.

The geography of NTAG encompasses all localities and places within the North East and North Cumbria ICS.

The Northern Treatment Advisory Group has a remit to manage the North East & North Cumbria ICB formulary.

Treatments which are specifically excluded from the remit of the group:

1. Treatments which are the responsibility of NHS England via specialised commissioning arrangements, including most cancer drugs and related treatments.